Toleranzia Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Toleranzia
Access all reports
Toleranzia AB is a biotechnology company specializing in the development of protein-based drugs for the treatment of autoimmune diseases. The company leverages its proprietary platform to create therapeutic proteins aimed at inducing immune tolerance in patients, addressing the underlying causes of autoimmune conditions rather than merely alleviating symptoms. Toleranzia focuses on diseases with significant unmet medical needs, striving to provide innovative treatments that can improve patients' quality of life. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
TOL
Country
🇸🇪 Sweden